Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Infographic: landmark trials in neuro-ophthalmology – results of the REVERSE trial for unilateral gene therapy rAAV2/2-ND4 in leber hereditary optic neuropathy – Nature
Infographic: landmark trials in neuro-ophthalmology – results of the REVERSE trial for unilateral gene therapy rAAV2/2-ND4 in leber hereditary optic neuropathy Nature Source: Author: | Date: 2025-07-16 07:00:00 Source: Author: | Date: 2025-07-16 07:00:00
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye – Nature
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye Nature Source: Author: | Date: 2025-07-15 07:00:00 Source: Author: | Date: 2025-07-15 07:00:00
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye – Nature
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye Nature Source: Author: | Date: 2025-07-04 07:00:00 Source: Author: | Date: 2025-07-04 07:00:00
Galimedix Begins Phase 2 Trial for GAL-101 in Dry AMD
Galimedix Therapeutics has announced the initiation of a phase 2 clinical study called eDREAM (NCT06659549), evaluating the efficacy and safety of GAL-101 eye drops in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). About the Phase 2…
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…
Opus Gets FDA SPA for APX3330 Phase 3 Trial
Opus Genetics has announced a key regulatory milestone, securing a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of APX3330. The oral treatment is being evaluated for moderate to…
EYLEA HD Succeeds in Phase 3 RVO Trial
Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (aflibercept 8 mg) has met its primary endpoint, marking a significant advancement in the treatment of retinal vein occlusion (RVO). About the QUASAR Trial The QUASAR trial…
Aurion’s AURN001 Shows Positive Phase 1/2 Results
Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN001, an allogeneic cell therapy product candidate for treating corneal edema secondary to corneal endothelial dysfunction. These results highlight the therapy’s potential as a groundbreaking treatment…
FDA Clears ViGeneron’s VG801 for Stargardt Disease
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene therapy candidate designed to treat Stargardt disease and other retinal dystrophies caused by mutations in the ABCA4 gene. This marks…